Ovid Therapeutics (OVID) Stock Overview
A biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OVID Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.75 |
| 52 Week High | US$3.11 |
| 52 Week Low | US$0.26 |
| Beta | -0.028 |
| 1 Month Change | 39.59% |
| 3 Month Change | 70.81% |
| 1 Year Change | 882.14% |
| 3 Year Change | -11.29% |
| 5 Year Change | -27.25% |
| Change since IPO | -77.55% |
Recent News & Updates
Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Recent updates
Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Oct 03Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Shareholder Returns
| OVID | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 25.0% | -0.1% | 3.4% |
| 1Y | 882.1% | 40.2% | 28.4% |
Return vs Industry: OVID exceeded the US Biotechs industry which returned 40.2% over the past year.
Return vs Market: OVID exceeded the US Market which returned 28.4% over the past year.
Price Volatility
| OVID volatility | |
|---|---|
| OVID Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: OVID's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OVID's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 23 | Meg Alexander | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc. Fundamentals Summary
| OVID fundamental statistics | |
|---|---|
| Market cap | US$362.66m |
| Earnings (TTM) | -US$17.14m |
| Revenue (TTM) | US$7.25m |
Is OVID overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVID income statement (TTM) | |
|---|---|
| Revenue | US$7.25m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.25m |
| Other Expenses | US$24.39m |
| Earnings | -US$17.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -236.38% |
| Debt/Equity Ratio | 0% |
How did OVID perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 14:36 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ovid Therapeutics Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |